Shell Asset Management CO Nektar Therapeutics Transaction History

Shell Asset Management CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$16.56 - $25.46 $179,874 - $276,546	-10,862 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $171,293 - $206,703	10,862 New	10,862 $185,000
Q4 2019 Feb 13, 2020	SELL	$15.87 - $23.12 $186,186 - $271,243	-11,732 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$31.0 - $36.3 $17,267 - $20,219	-557 Reduced 4.53%	11,732 $417,000
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $44,245 - $82,369	1,454 Added 13.42%	12,289 $404,000
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $470,639 - $693,803	-10,130 Reduced 48.32%	10,835 $661,000
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $32,560 - $73,532	704 Added 3.47%	20,965 $1.02 Million
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $471,483 - $890,726	-8,214 Reduced 28.85%	20,261 $2.15 Million
Q4 2017 Feb 09, 2018	SELL	$23.02 - $60.5 $521,103 - $1.37 Million	-22,637 Reduced 44.29%	28,475 $1.7 Million
Q3 2017 Oct 20, 2017	BUY	$17.79 - $24.0 $77,368 - $104,376	4,349 Added 9.3%	51,112 $1.23 Million
Q3 2017 Oct 18, 2017	BUY	$17.79 - $24.0 $831,913 - $1.12 Million	46,763	46,763 $564,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.